5-Hydroxytryptamine type 7 receptor neuroprotection against NMDA-induced excitotoxicity is PDGFβ receptor dependent

Journal of Neurochemistry

Volumn 125, Issue 1, 2013, Pages 26-36

  Vasefi, Maryam S ^a   Kruk, Jeff S ^a   Heikkila, John J ^a   Beazely, Michael A ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

5 HT7; hippocampus; neuroprotection; NMDA; NR2B; phosphorylation

Indexed keywords

G PROTEIN COUPLED RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PHOSPHOLIPASE C GAMMA; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR KINASE; SEROTONIN 7 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; ENZYME ACTIVITY; EXCITOTOXICITY; FETUS; HIPPOCAMPUS; INCUBATION TIME; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION;

ANIMALS; CELLS, CULTURED; HIPPOCAMPUS; MICE; N-METHYLASPARTATE; NEURONS; PHOSPHORYLATION; PIPERAZINES; PRIMARY CELL CULTURE; PROTEIN ISOFORMS; PROTEIN SUBUNITS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SEROTONIN; SEROTONIN RECEPTOR AGONISTS; TYPE C PHOSPHOLIPASES; UP-REGULATION;

EID: 84875251879     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12157     Document Type: Article

References (60)

1. Andressen K. W., Norum J. H., Levy F. O., and, Krobert K. A., (2006) Activation of adenylyl cyclase by endogenous G(s)-coupled receptors in human embryonic kidney 293 cells is attenuated by 5-HT(7) receptor expression. Mol. Pharmacol. 69, 207-215.
2. Arimura K., Ago T., Kamouchi M., Nakamura K., Ishitsuka K., Kuroda J., Sugimori H., Ooboshi H., Sasaki T., and, Kitazono T., (2012) PDGF receptor beta signaling in pericytes following ischemic brain injury. Curr. Neurovasc. Res. 9, 1-9.
3. Bacon W. L., and, Beck S. G., (2000) 5-Hydroxytryptamine(7) receptor activation decreases slow afterhyperpolarization amplitude in CA3 hippocampal pyramidal cells. J. Pharmacol. Exp. Ther. 294, 672-679.
4. Beazely M. A., Tong A., Wei W. L., Van Tol H., Sidhu B., and, MacDonald J. F., (2006) D2-class dopamine receptor inhibition of NMDA currents in prefrontal cortical neurons is platelet-derived growth factor receptor-dependent. J. Neurochem. 98, 1657-1663.
5. Beazely M. A., Lim A., Li H., Trepanier C., Chen X., Sidhu B., and, Macdonald J. F., (2009) Platelet-derived growth factor selectively inhibits NR2B-containing N-methyl-D-aspartate receptors in CA1 hippocampal neurons. J. Biol. Chem. 284, 8054-8063.
6. Bonaventure P., Dugovic C., Kramer M., et al,. (2012) Translational evaluation of JNJ-18038683, a 5-HT7 receptor antagonist, on REM sleep and in major depressive disorder. J. Pharmacol. Exp. Ther. 342, 429-440.
7. Carrier R. L., Ma T. C., Obrietan K., and, Hoyt K. R., (2006) A sensitive and selective assay of neuronal degeneration in cell culture. J. Neurosci. Methods 154, 239-244.
8. Chapin E. M., and, Andrade R., (2001a) A 5-HT(7) receptor-mediated depolarization in the anterodorsal thalamus. I. Pharmacological characterization. J. Pharmacol. Exp. Ther. 297, 395-402.
9. Chapin E. M., and, Andrade R., (2001b) A 5-HT(7) receptor-mediated depolarization in the anterodorsal thalamus. II. Involvement of the hyperpolarization-activated current I(h). J. Pharmacol. Exp. Ther. 297, 403-409.
10. Crider J. Y., Williams G. W., Drace C. D., Katoli P., Senchyna M., and, Sharif N. A., (2003) Pharmacological characterization of a serotonin receptor (5-HT7) stimulating cAMP production in human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 44, 4837-4844.
11. Duncan M. J., and, Congleton M. R., (2010) Neural mechanisms mediating circadian phase resetting by activation of 5-HT(7) receptors in the dorsal raphe: roles of GABAergic and glutamatergic neurotransmission. Brain Res. 1366, 110-119.
12. Egawa-Tsuzuki T., Ohno M., Tanaka N., Takeuchi Y., Uramoto H., Faigle R., Funa K., Ishii Y., and, Sasahara M., (2004) The PDGF B-chain is involved in the ontogenic susceptibility of the developing rat brain to NMDA toxicity. Exp. Neurol. 186, 89-98.
13. Ellis J. A., Canoll P., McCormick P. C., 2nd, Feldstein N. A., Anderson R. C., Angevine P. D., Kaiser M. G., McCormick P. C., Bruce J. N., and, Ogden A. T., (2012a) Platelet-derived growth factor receptor (PDGFR) expression in primary spinal cord gliomas. J. Neurooncol. 106, 235-242.
14. Ellis J. A., Castelli M., Bruce J. N., Canoll P., and, Ogden A. T., (2012b) Retroviral delivery of PDGF to spinal cord progenitor cells drives the formation of intramedullary gliomas. Neurosurgery 70, 198-204.
15. Figiel M., Maucher T., Rozyczka J., Bayatti N., and, Engele J., (2003) Regulation of glial glutamate transporter expression by growth factors. Exp. Neurol. 183, 124-135.
16. Galici R., Boggs J. D., Miller K. L., Bonaventure P., and, Atack J. R., (2008) Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav. Pharmacol. 19, 153-159.
17. Gill C. H., Soffin E. M., Hagan J. J., and, Davies C. H., (2002) 5-HT7 receptors modulate synchronized network activity in rat hippocampus. Neuropharmacology 42, 82-92.
18. Harsing L. G., Jr, Prauda I., Barkoczy J., Matyus P., and, Juranyi Z., (2004) A 5-HT7 heteroreceptor-mediated inhibition of [3H]serotonin release in raphe nuclei slices of the rat: evidence for a serotonergic-glutamatergic interaction. Neurochem. Res. 29, 1487-1497.
19. Hirst W. D., Price G. W., Rattray M., and, Wilkin G. P., (1997) Identification of 5-hydroxytryptamine receptors positively coupled to adenylyl cyclase in rat cultured astrocytes. Br. J. Pharmacol. 120, 509-515.
20. van Hooft J. A., and, Vijverberg H. P., (2000) 5-HT(3) receptors and neurotransmitter release in the CNS: a nerve ending story? Trends Neurosci. 23, 605-610.
21. Hoyer S., (2002) The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J. Neural. Transm. 109, 991-1002.
22. Hoyer D., and, Martin G., (1997) 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 36, 419-428.
23. Iihara K., Sasahara M., Hashimoto N., Uemura Y., Kikuchi H., and, Hazama F., (1994) Ischemia induces the expression of the platelet-derived growth factor-B chain in neurons and brain macrophages in vivo. J. Cereb. Blood Flow Metab. 14, 818-824.
24. Iihara K., Sasahara M., Hashimoto N., and, Hazama F., (1996) Induction of platelet-derived growth factor beta-receptor in focal ischemia of rat brain. J. Cereb. Blood Flow Metab. 16, 941-949.
25. Kobe F., Guseva D., Jensen T. P., et al,. (2012) 5-HT7R/G12 signaling regulates neuronal morphology and function in an age-dependent manner. J. Neurosci. 32, 2915-2930.
26. Kovalenko M., Gazit A., Bohmer A., Rorsman C., Ronnstrand L., Heldin C. H., Waltenberger J., Bohmer F. D., and, Levitzki A., (1994) Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54, 6106-6114.
27. Krobert K. A., Bach T., Syversveen T., Kvingedal A. M., and, Levy F. O., (2001) The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution. Naunyn Schmiedebergs Arch. Pharmacol. 363, 620-632.
28. Krobert K. A., Andressen K. W., and, Levy F. O., (2006) Heterologous desensitization is evoked by both agonist and antagonist stimulation of the human 5-HT(7) serotonin receptor. Eur. J. Pharmacol. 532, 1-10.
29. Kroeze W. K., Kristiansen K., and, Roth B. L., (2002) Molecular biology of serotonin receptors structure and function at the molecular level. Curr. Top. Med. Chem. 2, 507-528.
30. Krupinski J., Issa R., Bujny T., Slevin M., Kumar P., Kumar S., and, Kaluza J., (1997) A putative role for platelet-derived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans. Stroke 28, 564-573.
31. Kvachnina E., Liu G., Dityatev A., Renner U., Dumuis A., Richter D. W., Dityateva G., Schachner M., Voyno-Yasenetskaya T. A., and, Ponimaskin E. G., (2005) 5-HT7 receptor is coupled to G alpha subunits of heterotrimeric G12-protein to regulate gene transcription and neuronal morphology. J. Neurosci. 25, 7821-7830.
32. Lai T. W., Shyu W. C., and, Wang Y. T., (2011) Stroke intervention pathways: NMDA receptors and beyond. Trends Mol. Med. 17, 266-275.
33. Leopoldo M., Lacivita E., De Giorgio P., Fracasso C., Guzzetti S., Caccia S., Contino M., Colabufo N. A., Berardi F., and, Perrone R., (2008) Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1- piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor activity. Part III. J. Med. Chem. 51, 5813-5822.
34. Mahe C., Bernhard M., Bobirnac I., Keser C., Loetscher E., Feuerbach D., Dev K. K., and, Schoeffter P., (2004) Functional expression of the serotonin 5-HT7 receptor in human glioblastoma cell lines. Br. J. Pharmacol. 143, 404-410.
35. Marcos B., Cabero M., Solas M., Aisa B., and, Ramirez M. J., (2010) Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects. Int. J. Neuropsychopharmacol. 13, 775-784.
36. Mork A., Pehrson A., Brennum L. T., et al,. (2012) Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J. Pharmacol. Exp. Ther. 340, 666-675.
37. Peng F., Dhillon N., Callen S., Yao H., Bokhari S., Zhu X., Baydoun H. H., and, Buch S., (2008) Platelet-derived growth factor protects neurons against gp120-mediated toxicity. J. Neurovirol. 14, 62-72.
38. Quintero J. E., and, McMahon D. G., (1999) Serotonin modulates glutamate responses in isolated suprachiasmatic nucleus neurons. J. Neurophysiol. 82, 533-539.
39. Roberts C., Thomas D. R., Bate S. T., and, Kew J. N., (2004) GABAergic modulation of 5-HT7 receptor-mediated effects on 5-HT efflux in the guinea-pig dorsal raphe nucleus. Neuropharmacology 46, 935-941.
40. Romero G., Pujol M., and, Pauwels P. J., (2006) Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists. Naunyn Schmiedebergs Arch. Pharmacol. 374, 31-39.
41. Roussidis A. E., Theocharis A. D., Tzanakakis G. N., and, Karamanos N. K., (2007) The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer. Curr. Med. Chem. 14, 735-743.
42. Sakata M., Yanamoto H., Hashimoto N., Iihara K., Tsukahara T., Taniguchi T., and, Kikuchi H., (1998) Induction of infarct tolerance by platelet-derived growth factor against reversible focal ischemia. Brain Res. 784, 250-255.
43. Shiba M., Suzuki H., Fujimoto M., Shimojo N., Imanaka-Yoshida K., Yoshida T., Kanamaru K., Matsushima S., and, Taki W., (2013) Role of platelet-derived growth factor in cerebral vasospasm after subarachnoid hemorrhage in rats. Acta Neurochir. Suppl. 115, 219-223.
44. Shih A. H., and, Holland E. C., (2006) Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 232, 139-147.
45. Smith B. N., Sollars P. J., Dudek F. E., and, Pickard G. E., (2001) Serotonergic modulation of retinal input to the mouse suprachiasmatic nucleus mediated by 5-HT1B and 5-HT7 receptors. J. Biol. Rhythms 16, 25-38.
46. Smits A., Kato M., Westermark B., Nister M., Heldin C. H., and, Funa K., (1991) Neurotrophic activity of platelet-derived growth factor (PDGF): Rat neuronal cells possess functional PDGF beta-type receptors and respond to PDGF. Proc. Natl Acad. Sci. USA 88, 8159-8163.
47. Soriano F. X., and, Hardingham G. E., (2007) Compartmentalized NMDA receptor signalling to survival and death. J. Physiol. 584, 381-387.
48. Stam N. J., Roesink C., Dijcks F., Garritsen A., van Herpen A., and, Olijve W., (1997) Human serotonin 5-HT7 receptor: cloning and pharmacological characterisation of two receptor variants. FEBS Lett. 413, 489-494.
49. Thomas D. R., and, Hagan J. J., (2004) 5-HT7 receptors. Curr. Drug Targets CNS Neurol. Disord. 3, 81-90.
50. Thomas D. R., Middlemiss D. N., Taylor S. G., Nelson P., and, Brown A. M., (1999) 5-CT stimulation of adenylyl cyclase activity in guinea-pig hippocampus: evidence for involvement of 5-HT7 and 5-HT1A receptors. Br. J. Pharmacol. 128, 158-164.
51. Tokarski K., Zahorodna A., Bobula B., Grzegorzewska M., Pitra P., and, Hess G., (2005) Repeated administration of citalopram and imipramine alters the responsiveness of rat hippocampal circuitry to the activation of 5-HT7 receptors. Eur. J. Pharmacol. 524, 60-66.
52. Toohey N., Klein M. T., Knight J., Smith C., and, Teitler M., (2009) Human 5-HT7 receptor-induced inactivation of forskolin-stimulated adenylate cyclase by risperidone, 9-OH-risperidone and other "inactivating antagonists". Mol. Pharmacol. 76, 552-559.
53. Tseng H. C., and, Dichter M. A., (2005) Platelet-derived growth factor-BB pretreatment attenuates excitotoxic death in cultured hippocampal neurons. Neurobiol. Dis. 19, 77-83.
54. Uzun S., Kozumplik O., Mimica N., and, Folnegovic-Smalc V., (2005) Aripiprazole: an overview of a novel antipsychotic. Psychiatr. Danub. 17, 67-75.
55. Valenzuela C. F., Xiong Z., MacDonald J. F., Weiner J. L., Frazier C. J., Dunwiddie T. V., Kazlauskas A., Whiting P. J., and, Harris R. A., (1996) Platelet-derived growth factor induces a long-term inhibition of N-methyl-D-aspartate receptor function. J. Biol. Chem. 271, 16151-16159.
56. Vasefi M. S., Kruk J. S., Liu H., Heikkila J. J., and, Beazely M. A., (2012) Activation of 5-HT7 receptors increases neuronal platelet-derived growth factor beta receptor expression. Neurosci. Lett. 511, 65-69.
57. Weigel M. T., Meinhold-Heerlein I., Bauerschlag D. O., Schem C., Bauer M., Jonat W., Maass N., and, Mundhenke C., (2009) Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. Cancer Lett. 273, 70-79.
58. Wu X., Zhu D., Jiang X., Okagaki P., Mearow K., Zhu G., McCall S., Banaudha K., Lipsky R. H., and, Marini A. M., (2004) AMPA protects cultured neurons against glutamate excitotoxicity through a phosphatidylinositol 3-kinase-dependent activation in extracellular signal-regulated kinase to upregulate BDNF gene expression. J. Neurochem. 90, 807-818.
59. Yao H., Peng F., Dhillon N., Callen S., Bokhari S., Stehno-Bittel L., Ahmad S. O., Wang J. Q., and, Buch S., (2009a) Involvement of TRPC channels in CCL2-mediated neuroprotection against tat toxicity. J. Neurosci. 29, 1657-1669.
60. Yao H., Peng F., Fan Y., Zhu X., Hu G., and, Buch S. J., (2009b) TRPC channel-mediated neuroprotection by PDGF involves Pyk2/ERK/CREB pathway. Cell Death Differ. 16, 1681-1693.